This site is intended for UK healthcare professionals only
NICE are recommending an innovative new drug, within the Cancer Drugs Fund, for treating advanced or recurrent endometrial cancer in adults who have had platinum-based chemotherapy.
This news story provides insight into how the immunotherapy treatment could benefit 124 people a year in England as a second-line treatment.
We do not endorse, approve, certify, or control any linked websites, their sponsors, or any of their policies, activities, products, or services. We do not assume responsibility for the accuracy, completeness, or timeliness of the information.
Visitors to any linked websites should not use or rely on the information contained therein.
Please click “Continue” to leave this website and proceed to the selected site.
This link takes you to a 3rd party website not controlled by us.
The site may contain information that has been created, published, maintained, or posted by institutions or organisations independent of the PCWHF.
We do not endorse, approve, certify, or control any linked websites, their sponsors, or any of their policies, activities, products, or services. We do not assume responsibility for the accuracy, completeness, or timeliness of the information.
Visitors to any linked websites should not use or rely on the information contained therein.
Please click “Continue” to leave this website and proceed to the selected site.
